These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909 [TBL] [Abstract][Full Text] [Related]
4. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Wei Q; Sheng L; Shui Y; Hu Q; Nordgren H; Carlsson J Ann Surg Oncol; 2008 Apr; 15(4):1193-201. PubMed ID: 18172732 [TBL] [Abstract][Full Text] [Related]
5. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122 [TBL] [Abstract][Full Text] [Related]
6. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825 [TBL] [Abstract][Full Text] [Related]
7. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817 [TBL] [Abstract][Full Text] [Related]
8. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164 [TBL] [Abstract][Full Text] [Related]
9. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Sun M; Behrens C; Feng L; Ozburn N; Tang X; Yin G; Komaki R; Varella-Garcia M; Hong WK; Aldape KD; Wistuba II Clin Cancer Res; 2009 Aug; 15(15):4829-37. PubMed ID: 19622585 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349 [TBL] [Abstract][Full Text] [Related]
11. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941 [TBL] [Abstract][Full Text] [Related]
12. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Wei Q; Chen L; Sheng L; Nordgren H; Wester K; Carlsson J Int J Oncol; 2007 Sep; 31(3):493-9. PubMed ID: 17671674 [TBL] [Abstract][Full Text] [Related]
13. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882 [TBL] [Abstract][Full Text] [Related]
14. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707 [TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978 [TBL] [Abstract][Full Text] [Related]
18. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study. Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Hirsch FR; Varella-Garcia M; Cappuzzo F Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294 [TBL] [Abstract][Full Text] [Related]
20. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Namba Y; Kijima T; Yokota S; Niinaka M; Kawamura S; Iwasaki T; Takeda Y; Kimura H; Okada T; Yamaguchi T; Nakagawa M; Okumura Y; Maeda H; Ito M Clin Lung Cancer; 2004 Sep; 6(2):123-8. PubMed ID: 15476598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]